Skip to main navigation
Logo

SEC Filings

SEC Filings

Filing date Form Description View
Jan 21, 2021 8-K

Report of unscheduled material events or corporate event

View HTML
0000950170-21-000010.pdf
0000950170-21-000010.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Jan 19, 2021 4

Statement of changes in beneficial ownership of securities

View HTML
0001209191-21-003992.pdf
0001209191-21-003992.xls
Jan 11, 2021 8-K

Report of unscheduled material events or corporate event

View HTML
0000950170-21-000006.pdf
0000950170-21-000006.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Jan 8, 2021 8-K

Report of unscheduled material events or corporate event

View HTML
0000950170-21-000003.pdf
0000950170-21-000003.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Jan 8, 2021 4

Statement of changes in beneficial ownership of securities

View HTML
0001209191-21-002825.pdf
0001209191-21-002825.xls
Jan 5, 2021 4

Statement of changes in beneficial ownership of securities

View HTML
0001209191-21-001583.pdf
0001209191-21-001583.xls
Dec 17, 2020 8-K

Report of unscheduled material events or corporate event

View HTML
0000950170-20-000111.pdf
0000950170-20-000111.xls
EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
Dec 10, 2020 SC 13D/A

An amendment to a SC 13D filing

View HTML
0001193125-20-314963.pdf
Dec 10, 2020 4

Statement of changes in beneficial ownership of securities

View HTML
0001209191-20-062733.pdf
0001209191-20-062733.xls
Dec 7, 2020 8-K

Report of unscheduled material events or corporate event

View HTML
0000950170-20-000108.pdf
0000950170-20-000108.xls
EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page Next ›
  • Last page Last »
Investors

    Investor Relations

    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • SEC Filings
    • Stock Information
    • Analyst Coverage
    • Investor FAQ
    • Contact Us

    Shareholder Tools

    • Email Alerts
    • Print
    • Share

  • Facebook
  • LinkedIn
  • Twitter
  • RSS
  • About
    • Management
      • Emil D. Kakkis, M.D., Ph.D.
      • Jayson Dallas, M.D.
      • Dennis Huang
      • Thomas Kassberg
      • Karah Parschauer
      • John Pinion
      • Shalini Sharp
    • Board of Directors
      • Daniel G. Welch
      • Emil D. Kakkis, M.D., Ph.D.
      • William Aliski
      • Deborah Dunsire, M.D.
      • Lars Ekman, M.D., Ph.D.
      • Matthew K. Fust
      • Michael Narachi
      • Clay B. Siegall, Ph.D.
    • Grants & Charitable Contributions
    • Our Commitment to Patients
    • Message from BIO
  • Medicines
    • Crysvita®
    • Mepsevii™
    • Dojolvi™
  • Pipeline
    • DTX 301 for OTC
    • DTX 401 for GSDIa
    • Presentations & Publications
  • For Patients
    • XLH
    • TIO
    • MPS 7
    • LC-FAOD
    • OTC
    • GSD1a
    • Access to Approved Therapies
    • Access to Investigational Therapies
  • Investors

      Investors

      • Press Releases
      • Events & Presentations
      • Corporate Governance
      • SEC Filings
      • Stock Information
      • Analyst Coverage
      • Investor FAQ
      • Contact Us
  • Careers
    • Culture
    • Benefits
    • Talent Network
    • Jobs
  • Partnering
    • Current Partnerships
  • Contact
  • About
    • Management
      • Emil D. Kakkis, M.D., Ph.D.
      • Jayson Dallas, M.D.
      • Dennis Huang
      • Thomas Kassberg
      • Karah Parschauer
      • John Pinion
      • Shalini Sharp
    • Board of Directors
      • Daniel G. Welch
      • Emil D. Kakkis, M.D., Ph.D.
      • William Aliski
      • Deborah Dunsire, M.D.
      • Lars Ekman, M.D., Ph.D.
      • Matthew K. Fust
      • Michael Narachi
      • Clay B. Siegall, Ph.D.
    • Grants & Charitable Contributions
    • Our Commitment to Patients
    • Message from BIO
    • Medicines
      • Crysvita®
      • Mepsevii™
      • Dojolvi™
  • Pipeline
    • DTX 301 for OTC
    • DTX 401 for GSDIa
    • Presentations & Publications
  • For Patients
    • XLH
    • TIO
    • MPS 7
    • LC-FAOD
    • OTC
    • GSD1a
    • Access to Approved Therapies
    • Access to Investigational Therapies
  • Investors

      Investors

      • Press Releases
      • Events & Presentations
      • Corporate Governance
      • SEC Filings
      • Stock Information
      • Analyst Coverage
      • Investor FAQ
      • Contact Us
  • Careers
    • Culture
    • Benefits
    • Talent Network
    • Jobs
    Partnering
    • Current Partnerships
    Contact
    • Driving Directions
  • Privacy Policy
© 2021 Ultragenyx Pharmaceutical Inc.Website Design: Hane Chow, Inc.
  • Privacy Policy
  • Cookie Policy